atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation:

Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Monday, March 3 at 11:50 A.M. ETWebcast link: Here

An archived replay will be available on the Investors section of the atai website under Events for up to 90 days.

About atai Life Sciencesatai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The Company was founded in response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to developing novel, evidence-based therapeutics to treat depression, anxiety and other mental health disorders. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.

Contact Information

Investor Contact:IR@atai.life

Media Contact:PR@atai.life

ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more ATAI Life Sciences NV Charts.
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more ATAI Life Sciences NV Charts.